Ascendis Pharma A/S (NASDAQ:ASND) Shares Sold by First Turn Management LLC

First Turn Management LLC decreased its holdings in Ascendis Pharma A/S (NASDAQ:ASND) by 19.3% in the 3rd quarter, Holdings Channel reports. The firm owned 150,593 shares of the biotechnology company’s stock after selling 35,988 shares during the period. Ascendis Pharma A/S accounts for about 3.6% of First Turn Management LLC’s investment portfolio, making the stock its 8th biggest holding. First Turn Management LLC’s holdings in Ascendis Pharma A/S were worth $22,485,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of ASND. Signaturefd LLC raised its holdings in Ascendis Pharma A/S by 13.2% in the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 80 shares during the period. Profund Advisors LLC boosted its holdings in shares of Ascendis Pharma A/S by 3.0% during the second quarter. Profund Advisors LLC now owns 2,919 shares of the biotechnology company’s stock valued at $398,000 after acquiring an additional 85 shares during the period. Rhumbline Advisers raised its stake in shares of Ascendis Pharma A/S by 10.3% during the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock valued at $209,000 after purchasing an additional 143 shares in the last quarter. Thrivent Financial for Lutherans raised its stake in shares of Ascendis Pharma A/S by 0.3% during the third quarter. Thrivent Financial for Lutherans now owns 78,473 shares of the biotechnology company’s stock valued at $11,717,000 after purchasing an additional 228 shares in the last quarter. Finally, Bessemer Group Inc. raised its position in Ascendis Pharma A/S by 61.0% in the first quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock worth $132,000 after acquiring an additional 332 shares in the last quarter.

Ascendis Pharma A/S Price Performance

NASDAQ ASND opened at $122.00 on Tuesday. Ascendis Pharma A/S has a one year low of $90.13 and a one year high of $161.00. The business has a 50 day simple moving average of $132.40 and a 200 day simple moving average of $132.47. The stock has a market capitalization of $7.40 billion, a P/E ratio of -15.10 and a beta of 0.66.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The business had revenue of $38.75 million during the quarter, compared to analysts’ expectations of $94.74 million. Equities analysts expect that Ascendis Pharma A/S will post -7.3 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. TD Cowen cut their price objective on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a report on Friday. Citigroup boosted their price target on Ascendis Pharma A/S from $178.00 to $207.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th. Evercore ISI boosted their target price on Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an “outperform” rating in a report on Tuesday, September 17th. StockNews.com lowered Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a report on Tuesday, November 12th. Finally, The Goldman Sachs Group upped their price target on Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th. One analyst has rated the stock with a sell rating, one has given a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, Ascendis Pharma A/S currently has a consensus rating of “Moderate Buy” and an average price target of $191.77.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.